For a highly heterogeneous tumor cell population comprised of HGF treated 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R, T790M mutations, the predicted fifteen day switching therapy (afatinib/trametib followed by erlotinib/crizotinib) provides an immediate benefit versus the predicted constant treatment strategy (afatinib/trametinib), yielding a 10-fold decrease in final tumor population. This evidence concerns the gene HGF and neoplasm.